variable expression in AR disorders is perhaps less rare than assumed. (6) Interestingly, de novo AR gene mutations are not mentioned as a possible cause for reduced segregation ratios in AR disorders. As new AR mutations usually have no phenotypic effect, we therefore know very little about mutation rates in this category, but there is no reason to assume that they are rarer than de novo autosomal dominant or X linked mutations. The evolving plethora of mutations in the CFTG gene would appear to prejudice this idea. However, as yet, no proven new mutations have been found among more than 700 families analysed in the Netherlands (D Hailey, Rotterdam, and H Scheffer, Groningen, personal communications). From the CHH families, only two out of 83 couples were consanguineous and here the mutated alleles are very likely to be identical by descent, although DNA analysis sometimes proves there are exceptions to this rule. Twenty families could be linked genealogically and here the unlinked mutation could be present even perhaps new, as in the other 61 CHH families. Only when the CHH gene, recently assigned to chromosome 9, is analysed for mutations will the point be clarified, either by proving or excluding the absence of the mutation in the father (with proven paternity) or absence of the mutation in the mother (apparent 'non-maternity'), when isosomdy has been excluded.

(7) Gonadal mosaicism for an AR mutation in one of the parents could theoretically be yet another cause of low segregation ratios in AR phenotypes. However, this will be difficult to distinguish from the above mentioned new AR mutation.

(8) Finally, unstable mutations, as in fragile X syndrome, myotonic dystrophy, Huntington's disease, could play a role in AR disorders. Since damage of gene function only occurs in a certain percentage of gametes in which the gene is segregating, the number of expected affected offspring will be reduced. In conclusion there are a number of possible explanations for a segregation ratio lower than 0.25, which endorses the conclusion of Bundey and Young. Until we know more about the relative importance of all these factors in several AR disorders, we will have to counsel with caution.

Jan C. OOSTERWIJK
Clinical Genetics Centre Leiden, PO Box 9600, 2300 RC Leiden, The Netherlands.


Prevention of Mediterranean anaemia in Latium, Italy, today

In four previous papers published in this Journal 1-4, we have presented the continuing programme for the prevention of Mediterranean anaemia (thalassaemia major) in Latium, a region of central Italy. This work, supported by the Regional Health Authorities of Latium, has been carried out by the Rome Microcythemia Institute since October 1975. It consists of the following.

(1) An educational programme among school children in Latium that consists of two steps. The first is detailed information provided class by class with brief lectures and printed and audiovisual material. The second is screening of informed students who have obtained consent to be examined from their parents.

(2) Examination of thalassaemic students' families and identification of carriers of the thalassaemia trait.

(3) The provision of information and screening campaigns to young adult school leavers. In this way, the information is imparted at meetings at the Family Health Services, in explanatory pamphlets at the marital Registry Offices in the towns and villages of the region, by information in the Public Health Offices and family doctors or gynaecologists, and recurrent use of the media.

Screening of school leavers evolved in 1978 through the effect of the school screening and has progressively increased. It is carried out in the outpatients department of the Institute and in the Family Health Services of the region.

The results of this continuing work are shown in the table. Young carriers of non-α thalassaemia comprise about 80% of all carriers in Latium (44,000 in a region with 2,000,000 inhabitants of childbearing age and an incidence of non-α thalassaemia of 0.02%).

The couple of childbearing age at risk identified (369) comprise 74% of the total (about 500) in Latium. All these couples are kept under surveillance by our genetic selling service. In the last 11 years homozgyotic fetuses have been aborted after prenatal diagnosis. The incidence of newborns affected by Mediterranean anaemia has decreased from 16-04 of 100,000 live births in 1975-76 to 1-97 in 1989-90. In 1991 and 1992 no affected children have been born in Latium.

This programme offers young thalassae- mic couples the advantage of choosing either postconceptional or preconceptional means of prevention.

The authors would like to thank the Health Authorities of Latium for financial support, the school directors and teachers, the many doctors, and co-workers G Ricotti, C Trenta, M Ballante, A Ferraggioli, E Lardi, S Sturza and their valuable collaboration.


Del(18p) syndrome with a single central maxillary incisor

In 1991 Aughton et al. reported a case of del(18p) syndrome and a single central maxillary incisor (SCMI), stating that it was only the second report of a patient with this association. They considered that the only former report was that of Dolan et al., however Boudailliez et al. had already described a similar case in 1983, which deserves attention.

ESTELA MORALES PERALTA
Centro Nacional de Genetica Medica, Escuela de Medicina Victorina Domínguez, 146 No 3102 Playa, Ciudad de la Habana, Cuba.


Results of the Latium thalassaemia prevention programme (October 1975 to June 1993)

Population screening

Secondary school students
Young adults
Total
Non-α thalassaemia carriers
Secondary school students
Young adults
Total
282,430
164,705
922,805
817,420
173,080
947,680
47
Total
364,063
19
Homozygous fetuses aborted from 1982 to 1991
From prospective couples
From retrospective couples
Total
59
69
1 BIANCO I B GRAZIANI B M ALESSI D PONZINI M C ALIQUIO A AMATO E FOGLIETTA M P CAPPARONI E GRECO P DI BAGIO N D’ARCANGELI S RINALDI
Prevention of Mediterranean anaemia in Latium, Italy, today.

I Bianco, B Graziani, M Lerone, D Ponzini, M C Aliquò, A Amato, E Foglietta, M P Cappabianca, E Greco and P D Di Biagio

*J Med Genet* 1994 31: 86
doi: 10.1136/jmg.31.1.86-a

Updated information and services can be found at:
http://jmg.bmj.com/content/31/1/86.2.citation

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/